

\_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

Product Information®  Information du Produit®

## ANNOUNCING A NEW IMAGE FOR VOLTAREN\* PHARMA PRODUCTS

Novartis Pharmaceuticals Canada Inc. is pleased to announce that all Voltaren\* Pharma sku's will be adopting a fresh, dynamic new image.

Over the next 12-18 months we will transition from the current packaging to the new packaging. Please note that there is no change to product DIN or UPC codes, please deplete your current Voltaren\* stock before distributing the new packages.

Should customers have any questions or concerns about the new packaging, please direct them to the Novartis Medical Information department @ 1-800-363-8883.

\* Voltaren is a registered trademark

Product Information®  Information du Produit®

## DO YOU STOCK RELPAX® 40 MG TABLETS?

Increased promotional efforts are now underway in your area. RELPAX® 40 mg blister packs of 6 tablets

Contact your local wholesaler to place an order today.

RELPAX tablets are indicated for the acute treatment of migraine with or without aura in adults. RELPAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of RELPAX tablets have not been established for cluster headache, which is present in an older, predominantly male population.

For complete information on contraindications, warnings, precautions and dosing guidelines please refer to the Product Monograph. The Product Monograph is available upon request from Pfizer Canada Inc., 17300 Trans-Canada Highway, Kirkland, Quebec H9J 2M5.

Reference: RELPAX Product Monograph, Pfizer Canada Inc., April 2009.

RELPAX® Pfizer Products Inc., owner/Pfizer Canada Inc., Licensee © 2010 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



Working together for a healthier world™



New Product®  Nouveau Produit®

### Important new product launch



Purdue Pharma would like to announce the launch of "BuTrans"™ 5, 10 and 20 mcg/h transdermal patches (buprenorphine transdermal system). BuTrans is an opioid schedule 1 narcotic.

We ask that you incorporate the following information concerning new "BuTrans"™ 5, 10 and 20 mcg/h transdermal patches into your current database.

"BuTrans"™: Buprenorphine transdermal delivery system

Strength	DIN	Product Code	McKesson Canada	AmerisourceBergen Canada Corporation	Kohl & Frisch Ltd
5 mcg/hr	02341174	66615	591172	2166615	110138
10 mcg/hr	02341212	66630	591248	2166630	110130
20 mcg/hr	02341220	66660	591321	2166660	110131

Pack Size:	Wholesale / Hospital Price per carton (4 patches):	TPD Schedule:
4 patches/carton	5 mcg/hr \$48.36	Narcotic (CDSA I)
	10 mcg/hr \$88.68	Availability:
	20 mcg/hr \$161.20	May 25, 2010


BuTrans™ product information is now also available in the Compendium of Pharmaceuticals and Specialties, online version (e-CPS).

™Purdue Pharma, owner of the registered trademark BuTrans © 2010 Purdue Pharma. All rights reserved.

Purdue Pharma Inc.  
General Partner of Compendium de  
**Purdue Pharma**  
 Pickering, Ontario L1W 5W6



## PRx PRESCRIPT® Sample Vouchers



- **Flexible** to maximize patient sample initiations
- **Offers** multiple formats to leverage any promotion
- **Guarantees** a return on investment
- **Lowers** the cost of delivering patient samples
- **Increases** the safety and integrity of your drug samples
- **Extends** the reach beyond your current target physicians

Visit us at [www.ipharmadirect.com](http://www.ipharmadirect.com)



RELPAX (eletriptan hydrobromide) is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of RELPAX have not been established for cluster headache, which is present in an older, predominantly male population.

For complete prescribing information, please refer to the Product Monograph.

The Product Monograph is available upon request from Pfizer Canada Inc., 17300 Trans-Canada Highway, Kirkland, Quebec H9J 2M5.

Reference: RELPAX Product Monograph, Pfizer Canada Inc., April 2009.



RELPAX® Pfizer Products Inc., owner/Pfizer Canada Inc., Licensee © 2010 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



## Now a full formulary benefit in Saskatchewan<sup>1</sup>

Prescribe Omnaris<sup>®</sup> for powerful relief of Allergic Rhinitis with an excellent tolerability profile.<sup>2</sup>

Distributor	Product Order Code	Distributor	Product Order Code
McKesson	691444	Le Groupe Jean Coutu	767 317
Matrix	6632004007	McMahon	506806
Kohl & Frisch	99385	Lawton's Wholesale	926854
AmerisourceBergen	AT00400		

OMNARIS<sup>®</sup> is indicated for the treatment of seasonal allergic rhinitis, including hayfever, and perennial allergic rhinitis in adults and adolescents 12 years of age and older. OMNARIS<sup>®</sup> should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract.

The most common adverse reactions reported with OMNARIS<sup>®</sup> vs. placebo in short-term clinical trials were epistaxis (2.7% vs. 2.1% placebo), nasal passage irritation (2.4% vs. 2.2% placebo) and headache (1.3% vs. 0.7% placebo). The most common adverse reactions reported with OMNARIS<sup>®</sup> vs. placebo in a 52-week clinical trial in patients 12 years of age and older with PAR were epistaxis (8.4% vs. 6.3% placebo), nasal passage irritation (4.3% vs. 3.6% placebo) and headache (1.6% vs. 0.5% placebo).

OMNARIS<sup>®</sup> should be used with caution, if at all, in patients with untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections,

or ocular herpes simplex. Patients who are on drugs that suppress the immune system are more susceptible to infections than healthy individuals. Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.

To minimize the systemic effects of intranasal corticosteroids, each patient should be titrated to his/her lowest effective dose. In patients who have asthma or other clinical conditions requiring long-term systemic corticosteroid treatment, rapid decreases in systemic corticosteroid dosages may cause severe exacerbation of their symptoms. There are no adequate studies with OMNARIS<sup>®</sup> in pregnant women.

Product Monograph available upon request.

**REFERENCE: 1.** SK Health: Drug Plan and Extended Benefits Branch. <http://formulary.drugplan.health.gov.sk.ca>  
**2.** Omnaris<sup>™</sup> (ciclesonide nasal spray) Product Monograph. Nycomed Canada Inc. April 2008.



© 2010 Nycomed Canada Inc. All rights reserved.  
 © Registered trademark of Nycomed GmbH. Used under licence.  
 ™ Trademark of Nycomed GmbH. Used under licence.

### FREE CLASSIFIED ADVERTISING FOR PHARMACISTS



**FAX:**  
1-800-420-3616



**EMAIL:**  
[contact@ipharmadirect.com](mailto:contact@ipharmadirect.com)

#### CATEGORY

- Career Opportunities
- Pharmacy for Sale
- Pharmacy Wanted
- For Sale - Pharmacy Store/Equipment
- Pharmacist Available
- Vacation Spots
- Seminars / Courses
- For Sale - Miscellaneous
- Reunions / Other

**If you would like to receive PharmaDirect by email, please provide your email address:**

Name: \_\_\_\_\_

Email: \_\_\_\_\_

Name: \_\_\_\_\_

Email: \_\_\_\_\_

**Fax Back to: 1-800-420-3616**

**Visit us at**  
**[www.ipharmadirect.com](http://www.ipharmadirect.com)**